Skip to main content

ADVERTISEMENT

Rick Lifsitz, MBA

Corrigendum
08/02/2016
Rick Lifsitz, MBA
Larry Blandford, PharmD—Column Editor
In the June 2016 article, “Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?"1 the author and column editor would like to clarify several points....
In the June 2016 article, “Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?"1 the author and column editor would like to clarify several points....
In the...
08/02/2016
Journal of Clinical Pathways
Pharma Insights
06/20/2016
Rick Lifsitz, MBA
Larry Blandford, PharmD—Column Editor
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The...
06/20/2016
Journal of Clinical Pathways